Morphine News and Research RSS Feed - Morphine News and Research

Morphine is an extremely potent opiate analgesic psychoactive drug and is considered to be the prototypical opioid. In clinical medicine, morphine is regarded as the gold standard, or benchmark, of analgesics used to relieve severe or agonizing pain and suffering.
EGPAF and ACS partner to improve access to essential pain medications for HIV people

EGPAF and ACS partner to improve access to essential pain medications for HIV people

Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the American Cancer Society (ACS) announced a new partnership to improve access to essential pain medications for people living with HIV in Swaziland. [More]
New study finds highest rates of decline in prescription drug misuse nationwide

New study finds highest rates of decline in prescription drug misuse nationwide

Five states that have implemented multi-faceted prescription drug abuse prevention programs in recent years showed the highest rate of decline in prescription drug misuse rates nationwide, according to a new study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services. [More]
Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation. [More]
Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

AcelRx Pharmaceuticals, Inc. and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment. [More]
CHOP study: Children with specific gene variants may require higher doses of pain-control drugs

CHOP study: Children with specific gene variants may require higher doses of pain-control drugs

In the first genome-wide analysis of postsurgical pain in children, pediatric researchers identified variations in genes that affect a child's need for pain-control drugs. The findings suggest that at some point physicians may calibrate pain-medication dosages according to a child's individual genetic makeup. [More]
Bone marrow transplantation shows promising results among patients with severe sickle cell disease

Bone marrow transplantation shows promising results among patients with severe sickle cell disease

Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA. [More]
Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

University of Iowa researchers have discovered a new form of neurotransmission that influences the long-lasting memory created by addictive drugs, like cocaine and opioids, and the subsequent craving for these drugs of abuse. Loss of this type of neurotransmission creates changes in brains cells that resemble the changes caused by drug addiction. [More]
Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. [More]
BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain. [More]
Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena, Inc. (NASDAQ:TRVN) today announced positive results from its Phase 1 trial of TRV734, which Trevena is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids. [More]
Physician describes ways to combat post-cancer pain

Physician describes ways to combat post-cancer pain

More and more people are surviving their cancer. Unfortunately, sometimes survival can come with pain. Although many people won't feel any pain after their cancer treatment, some may have chronic, bothersome pain. [More]
Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

When the body receives an injury to the skin, a signal is sent to the brain, which generates a sensation of pain. [More]
Use of opioid linked to higher levels of dissatisfaction following spine surgery

Use of opioid linked to higher levels of dissatisfaction following spine surgery

A new study appearing in the Journal of Bone and Joint Surgery (JBJS) links the use of opioid pain relievers (prescription medications, such as Percocet) to less improvement and higher levels of dissatisfaction following spine surgery. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAILâ„¢ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]
Nerve block technique offers potentially speedier recovery for orthopedic surgery patients

Nerve block technique offers potentially speedier recovery for orthopedic surgery patients

A Virginia Mason study has determined that a nerve block technique which avoids the femoral nerve results in the need for less morphine and a potentially speedier recovery for orthopedic surgery patients. [More]

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain. [More]
State highlights: New abortion restrictions in Louisiana; aging gracefully in the Gopher State

State highlights: New abortion restrictions in Louisiana; aging gracefully in the Gopher State

A bill that could result in the shuttering of up to four of Louisiana's five abortion clinics overwhelmingly received full passage from the Louisiana Legislature Wednesday (May 21), and Gov. Bobby Jindal has indicated he will sign it into law. The legislation is, in part, based on a similar measure passed in Texas last year and led to the closing of several abortion clinics in that state. In its last legislative hurdle, the House concurred an amendment on Wednesday (May 21) that was added to the bill on the Senate side (Lane, 5/22). [More]

Regulators vote against approving new painkiller

A key government panel Tuesday voted unanimously against approval of a powerful opioid prescription painkiller intended to provide faster relief with fewer side effects. At the conclusion of a hearing, the Food and Drug Administration advisory committee voted 14-0 against recommending that the agency approve Moxduo, the first drug to combine morphine and oxycodone into one capsule (Stein, 4/22). [More]
First Edition: April 23, 2014

First Edition: April 23, 2014

Today's headlines include a range of health policy news reports, including developments related to the health law, to the marketplace and at the state level. [More]
New drug multiplies analgesic effect of opioids without increasing constipation

New drug multiplies analgesic effect of opioids without increasing constipation

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine. [More]